Anemia on Chronic Disease in Leprosy Before and After Completing Multi Drug Therapy

Authors

  • Ni Kadek Setyawati Dermatology and Venerology Study Program, Faculty of Medicine, Universitas Udayana, Indonesia
  • Luh Made Mas Rusyati Dermatology and Venerology Study Program, Faculty of Medicine, Universitas Udayana, Indonesia
  • I Gusti Ayu Agung Elis Indira Dermatology and Venerology Study Program, Faculty of Medicine, Universitas Udayana, Indonesia
  • I Gusti Ayu Agung Praharsini Dermatology and Venerology Study Program, Faculty of Medicine, Universitas Udayana, Indonesia
  • I Gusti Nyoman Darmaputra Dermatology and Venerology Study Program, Faculty of Medicine, Universitas Udayana, Indonesia
  • I Gusti Ayu Agung Dwi Karmila Dermatology and Venerology Study Program, Faculty of Medicine, Universitas Udayana, Indonesia

DOI:

https://doi.org/10.59188/eduvest.v4i9.1500

Keywords:

Anemia On Chronic Disease, Erythrocyte Index, Leprosy, Multidrug Therapy

Abstract

Leprosy infection can cause anemia due to chronic disease (ACD). Multidrug therapy (MDT) for leprosy patients can overcome the infection. This study aims to determine the comparison in the incidence of ACD before and three months after MDT to leprosy patients at Prof. Dr. I G.N.G. Ngoerah Central General Hospital. A cross-sectional analytical observational study was conducted using secondary data from medical records of leprosy patients. A total of 142 samples were taken through total sampling. Data taken included gender, domicile, type of leprosy suffered, incidence of ACD, hemoglobin levels, and erythrocyte index before and three months after completing MDT leprosy therapy. Data analysis was carried out with SPSS version 21 using chi-square and paired t tests (dependent t-test), p value <0.05 means significant. The incidence of ACD was significantly higher before leprosy MDT therapy compared to 3 months after completing leprosy MDT therapy (49.3% vs. 16.2%; p value <0.001) with a prevalence ratio of 3.043 (2.021-4.584) CI95%. The mean hemoglobin levels, MCV, MCH, and MCHC levels 3 months after MDT leprosy therapy were significantly higher than before receiving MDT therapy (13.73 ± 1.47 vs. 12.40 ± 2.06 g/dL; p value <0.001), (88.18±7.22 vs. 84.07±9.55 fl; p value<0.001), (28.32±2.76 vs. 26.72±3.17 pg/cell; p value <0.001), (32.03±1.30 vs. 31.69±1.47%; p value<0.001). The incidence of ACD was significantly higher before MDT compared to 3 months after MDT. Mean hemoglobin, MCV, MCH, and MCHC levels were found to be significantly higher 3 months after MDT compared to before receiving MDT.

References

Amalia, H., Tabri, F., Vitayani, S., & Petellongi, I. (2017). Hemoglobin and ferritin serum levels on leprosy patients before multi drug therapy-world health organization (Mdt-Who) compared with healthy control group. International Journal of Sciences: Basic and Applied Research, 36(4), 74–82.

Cambau, E., & Williams, D. L. (2019). Anti-leprosy drugs: Modes of action and mechanisms of resistance in mycobacterium leprae. International Textbook of Leprosy.

Cappellini, M. D., & Motta, I. (2015). Anemia in clinical practice—definition and classification: does hemoglobin change with aging? Seminars in Hematology, 52(4), 261–269.

Cruz, R. C. da S., Bührer-Sékula, S., Penna, M. L. F., Penna, G. O., & Talhari, S. (2017). Leprosy: current situation, clinical and laboratory aspects, treatment history and perspective of the uniform multidrug therapy for all patients. Anais Brasileiros de Dermatologia, 92(6), 761–773.

Dupnik, K. M., Cardoso, F. J. R., De Macêdo, A. L. B. B., De Sousa, I. L. C., Leite, R. C. B., Jerônimo, S. M. B., & Nobre, M. L. (2013). Intolerance to leprosy multi-drug therapy: more common in women? Leprosy Review, 84(3), 209–218.

Gupta, B., Gupta, S., Chaudhary, M., Raj, A. T., Awan, K. H., & Patil, S. (2020). Hematological alterations in lepromatous leprosy: A cross-sectional observational study. Disease-a-Month, 66(7), 100919.

Islam, A. T., & Islam, R. (2016). Multi drug therapy effects on routine laboratory parameters in Leprosy patients. International Journal of Sciences & Applied Research (IJSAR), 3(3), 13–19.

Lubis, R. D. (2022). Anemia Pada Penyakit Kusta. Universitas Sumatera Utara.

Muhaira, W. T., Darmi, M., & Lubis, R. D. (2018). Hemolytic anemia incident in leprosy patients receiving multi-drug therapy at Haji Adam Malik Central Hospital, Medan-Indonesia. Bali Medical Journal, 7(2).

Riccò, M., Vezzosi, L., Balzarini, F., Mezzoiuso, A. G., Ranzieri, S., Vaccaro, F. G., Odone, A., & Signorelli, C. (2019). Epidemiology of leprosy in Italy (1920-2019): a comprehensive review on existing data. Acta Bio Medica: Atenei Parmensis, 90(Suppl 9), 7.

Sadeli, M. S. (2022). Hubungan Kadar Indeks Eritrosit dengan Morfologi Anemia yang Terjadi Pada Pasien Kusta Sebelum Pemberian Terapi: Penelitian Data Sekunder. Tesis. Universitas Udayana.

Singh, H., Nel, B., Dey, V., Tiwari, P., & Dulhani, N. (2011). Adverse effects of multi-drug therapy in leprosy, a two years’ experience (2006–2008) in tertiary health care centre in the tribal region of Chhattisgarh State (Bastar, Jagdalpur). Leprosy Review, 82(1), 17–24.

Suega, K. (n.d.). ASPEK BIOLOGIK DAN KLINIK BESI: DARI ANEMIA DEFISIENSI BESI SAMPAI ANEMIA DENGAN KELEBIHAN BESI.

Downloads

Published

2024-09-20

Most read articles by the same author(s)